Canaccord initiated coverage of Curaleaf (CURLF) with a Buy rating and C$5 price target The winds of regulatory change are finally starting to blow and any material change to the backdrop ahead of the midterm elections will drive a re-rating of the space, the analyst tells investors in a research note. Curaleaf continues to elevate its offering, which should allow the company to better moat its footprint and either remain the cannabis destination of choice for consumers.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CURLF:
- Curaleaf Announces Executive Securities Disposition Plan
- Curaleaf to Announce Q3 2025 Financial Results
- Curaleaf opens new dispensaries in Florida and Ohio
- Curaleaf Joins S&P/TSX Composite Index, Boosting Cannabis Industry Credibility
- Curaleaf Joins S&P/TSX Composite Index, Boosting Market Visibility